M137

Methysergide maleate salt

solid

• Formule empirique (notation de Hill): C₂₁H₂₇N₃O₂ · C₄H₄O₄
• Numéro CAS: 129-49-7
• Poids moléculaire : 469.53
• Numéro CE : 204-950-9
• Numéro MDL: MFCD00083185
• Code UNSPSC : 12352200
• ID de substance PubChem : 24278129
• Nomenclature NACRES : NA.77

Propriétés

• Forme: solid
• Niveau de qualité: 100
• Couleur: white to off-white
• Solubilité: DMSO: >10 mg/mL; H₂O: 2 mg/mL
• Auteur: Novartis
• Chaîne SMILES: OC(=O)\C=C/C(O)=O.[H][C@@]12Cc3cn(C)c4cccc(C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO)c34
• InChI: 1S/C21H27N3O2.C4H4O4/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14;5-3(6)1-2-4(7)8/h5-8,10,14-15,19,25H,4,9,11-12H2,1-3H3,(H,22,26);1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-,15+,19-;/m1./s1
• Clé InChI: LWYXFDXUMVEZKS-ZVFOLQIPSA-N
• Informations sur le gène: human ... HTR1A(3350) , HTR1B(3351) , HTR1D(3352) , HTR1E(3354) , HTR1F(3355) , HTR2A(3356) , HTR2B(3357) , HTR2C(3358) , HTR7(3363)

Description

Application

Methysergide maleate salt has been used as a serotonin (5HT) receptor antagonist to evaluate the potential systemic effects of methysergide (METH) and 5-HT infusions on production and milk composition in multiparous Holstein cows. It may also be used as a serotonin receptor blocker to identify the serotonergic receptor type involved in the direct excitation of mitral cells in the main olfactory bulb.

Actions biochimiques/physiologiques

Methysergide maleate, also known as sansert, is a semisynthetic ergot alkaloid ergometrine derivative. Methysergide is a serotonin 1(5-HT1) receptor agonist and a nonselective 5-HT2 and 5-HT7 serotonin receptor antagonist. Methysergide maleate is used as a pharmacological agent to treat migraines and other vascular headaches. But, prolonged and uncontrolled use of this drug may cause Leriche′s syndrome, angina pectoris, acute ischemia of the limbs. In addition, gastrointestinal side effects, such as abdominal cramps, nausea, and diarrhea have also been observed in few patients.

Caractéristiques et avantages

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informations sur la sécurité

• Pictogrammes: GHS06
• Mention d'avertissement: Danger
• Mentions de danger: H301
• Conseils de prudence: P301 + P310
• Classification des risques: Acute Tox. 3 Oral
• Code de la classe de stockage: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable
• Équipement de protection individuelle: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges